Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9.

View in: PubMed

subject areas

Aged
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Female
Humans
Immunotherapy
Interleukin-2
Leukemia, Myeloid, Acute
Male
Middle Aged
Remission Induction
Survival Rate
Treatment Outcome

authors with profiles

Richard A. Larson